Speaker illustration

Professor Peter Ferdinandy

Semmelweis University, Budapest (Hungary)

Péter Ferdinandy, MD, PhD, MBA, FESC, FISHR has been recognized as Highly Cited Researcher in 2014, 2017, 2020, 2021, and 2022. He published more than 300 papers and 5 patent families. His work is cited more than 20000 times and his Hirsh index is 73. He received an MD diploma in 1991, a PhD in 1995, and an MBA in finance and quality management in 2004. He became a registered clinical pharmacologist in 1999. He did a postdoctoral training at the University of Alberta, Edmonton, Canada (1997-1999). He founded Pharmahungary Group, a group of R&D companies (www.pharmahungary.com) involved in more than 300 drug/medical device development projects since their foundation in the early 2000s. Currently he is the vice-rector for science and innovations of the Semmelweis University, Budapest, Hungary (www.semmelweis.hu) and the editor-in-chief of the British Journal of Pharmacology.

Recent advances in coronary ischaemic heart disease: a translational perspective

Event: Frontiers in CardioVascular Biomedicine 2024

Topic: Platelets, Haemostasis, Coagulation

Session type: Symposium

Thumbnail

Cardiotoxicity and cardio-protection: at the heart of metabolism

Event: Frontiers in CardioVascular Biomedicine 2024

Topic: Drugs, Drug Targets

Session type: Symposium

Thumbnail

Evolving targets in lipid lowering therapy

Event: EuroCVP 2023 – The annual meeting on advances in cardiovascular pharmacotherapy

Topic: Cardiovascular Pharmacotherapy

Session type: Teaching Course

Thumbnail

Novel insights into heart failure

Event: CBCS Summer School 2023

Topic: Basic Science

Session type: Symposium

Thumbnail

Molecular networks of disease: the diseaseome

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Genetics, Epigenetics, ncRNA

Session type: Special Session

Thumbnail

Network medicine in cardiology

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Genetics, Epigenetics, ncRNA

Session type: Symposium

Thumbnail

Extracellular vesicles in cardiovascular disease: hope and pitfalls

Event: Frontiers in CardioVascular Biology 2018

Topic: Cardiac Diseases

Session type: Workshop

Thumbnail

Dissecting the secretome in the "omics" era

Event: ESC Congress 2017

Topic: Metabolism and metabolic syndromes

Session type: Symposium

Thumbnail

From plaque to infarction: discovering novel therapeutic targets

Event: ESC Congress 2016

Topic: Developmental biology

Session type: Symposium

Thumbnail

Mitochondria: regulators of cardiovascular health

Event: ESC Congress 2016

Topic: Integrative physiology and control mechanisms

Session type: Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb